- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2019–2024 · research · R01
Biomaterial Drones for Image-Guided Drug Delivery during radiotherapy
Wilfred Ngwa · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2025 · program · P01
Immune Modulation After Allogeneic HCT
Robert Jon Soiffer · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2021 · research · R50
Validation of EP400 downstream effectors and potential therapeutic targets in Merkel cell carcinoma
Jingwei Cheng · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2023 · research · R01
Control of PGC1alpha Translation and Function
Bruce M. Spiegelman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · career development · K08
Understanding and addressing sub-optimal responses to CAR T cell therapy for Multiple Myeloma
Eric L Smith · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2026 · research · R35
Identification of Novel Oncogenic Signaling Pathways using Viral Perturbations
James A. Decaprio · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2022 · grant · PCRP
Targeting the Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer
Irene Lee · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2019–2024 · research · R01
CDC7 kinase in normal and cancer cells: potential implications for cancer treatment
Peter Sicinski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · research · R01
The Function of CDK5 in Metastasis
Peter Sicinski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2022 · research · R35
Targeting High-Risk Lymphoid Neoplasms
David Marc Weinstock · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2023 · career development · K00
Cancer Therapeutic Resistance: Implication of AcAPE1 Mediated DNA Repair and T-Cell Based Immunotherapy
Shrabasti Roychoudhury · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · cooperative agreement · U01
Defining mechanisms of immunotherapy resistance in head and neck squamous cell carcinomas
David A Barbie · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2025 · cooperative agreement · UH3
Assay Validation of a Circulating miRNA Test for Diagnosis and Monitoring of Malignant Germ Cell Tumors
Anne Lindsay Frazier · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2027 · research · R01
PGC1alpha Pathway: Novel Intracellular and Extracellular Mediators
Bruce M. Spiegelman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2026 · research · R35
Structure, mechanism, and pharmacology of BRAF and its partners in the RAS/RAF/MAP kinase pathway
Michael J Eck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · career development · K08
The roles of anti-apoptotic proteins BCL-XL and MCL1 in mediating survival of high-grade serous ovarian cancer following drug-induced DNA damage
Elizabeth Harmon Stover · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2021 · grant · PCRP
The RET Kinase Signaling Axis in Neuroendocrine Prostate Cancer Plasticity
Yuzhen Zhou · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2019–2024 · cooperative agreement · U24
Developing Informatics Technologies to Model Cancer Gene Regulation
Clifford Meyer · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · research · R01
Small molecules targeting hepatic glucose production and insulin resistance
Patrick Robert Griffin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · research · R50
Functions of Cyclin/CDK complexes in development and cancer
Yan Geng · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2026 · research · R35
Structure, mechanism, and pharmacology of BRAF and its partners in the RAS/RAF/MAP kinase pathway
Michael J Eck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2021 · research · R21
Individualizing surveillance mammography for older breast cancer survivors
Rachel Ann Freedman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · research · R01
CDK7 inhibitors as a new strategy to overcome treatment resistance in ER+ metastatic breast cancer
Rinath M. Jeselsohn · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · research · R50
Functions of Cyclin/CDK complexes in development and cancer
Yan Geng · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · career development · K08
Expectations for Pediatric Cancer Treatment (EXPECT): A Family-Centered Intervention to Prepare Parents for Pediatric Leukemia Therapy
Katie A. Greenzang · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2026 · research · R35
Reading mitochondrial apoptotic signaling to identify active cancer therapeutics
Anthony G Letai · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2026 · research · R35
Structure, mechanism, and pharmacology of BRAF and its partners in the RAS/RAF/MAP kinase pathway
Michael J Eck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2022 · fellowship · F32
Epigenetic Induction of Gliomagenesis in Neural Progenitor Cells
Gilbert J Rahme · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2023 · research · R01
Regulators of Cancer Immunotherapy Response
Myles A Brown · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2022 · grant · OCRP
Overcoming the Limitations of Endocrine Therapy for Ovarian Cancer
Myles Brown · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2019–2021 · research · R21
Individualizing surveillance mammography for older breast cancer survivors
Rachel Ann Freedman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2023 · grant · PCRP
Defining and Functionally Characterizing the Epigenome in Lethal Prostate Cancer
Matthew Freedman · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2019–2024 · research · R01
Cancer-Specific Targeting and Function of Mammalian SWI/SNF (BAF) Chromatin Remodeling Complexes
Cigall Kadoch · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019 · research
Using artificial intelligence to identify young women at elevated risk for breast cancer who would be missed by conventional risk assessment
Elizabeth Mittendorf · Dana-Farber Cancer Institute · funded by Breast Cancer Research Foundation
2019 · career development · Young Investigator Award
Elucidating the mechanisms of XRN1 genetic dependency in a subset of lung cancer cells
Tao Zou · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2019 · research · AACR-MPM Oncology Charitable Foundation Transformative Research Grant
Reconstructing the differentiation dynamics and genealogy of cancer cells
Sahand Hormoz · Dana-Farber Cancer Institute · funded by American Association for Cancer Research
2019 · career development · Young Investigator Award
Enhancing the response of multidrug-resistant myeloma cells to natural killer (NK) cells
Sara Gandolfi · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2019 · career development · Career Development Award
Enhancing Information, Preparation, and Shared Decision-Making about Long-term Outcomes of Pediatric Cancer and its Treatment
Katie Greenzang · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2019 · career development · Young Investigator Award
Mapping the Landscape of FGFR Inhibitor Resistance in Urothelial Carcinoma via Deep Evolutionary Profiling
Arvind Ravi · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2019 · career development · Young Investigator Award
Defining genomic determinants of response to chemoradiation in anal squamous cell carcinoma
David Konieczkowski · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
